Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

RELEVANT EVENT

Grifols has entered into an agreement with Atcn GmbH for the purchase of 100% of the shares of German based pharmaceutical company Haema AG ("Haema"), in exchange of a purchase price of €220 million on a debt free basis. The closing of the transaction is subject to the fulfillment of certain conditions, among others, the authorization of the purchase by applicable antitrust authorities.

With this acquisition, and subject to the conditions being fulfilled, Grifols will acquire the businesses currently held by Haema, collection of plasma for fractionation, which includes 35 collection centres spread throughout the territory of Germany, and three more under construction. Its headquarters are located in Leipzig with approximately 24,000m² (which include administration, production, storage and power station buildings) and also has a central laboratory in Berlin.

Haema employs about 1,100 people and collected almost 800,000 litres of plasma in the preceding financial year, coming from approximately 1 million donations.

In Barcelona, on 20 March 2018

Nuria Martín Barnés
Secretary to the Board of Directors